Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Anterior uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.
The global anterior uveitis treatment market is projected to witness considerable growth during the forecast period. The major factors contributing to the growth of the market include the increasing prevalence of anterior uveitis due to the rising incidence of optical infections. In addition, the rising medical tourism and an expected approval for products under clinical trial and development is further estimated to propel the market growth during the forecast period. The anterior uveitis treatment market is classified on the basis of therapeutics into corticosteroids, anti-inflammatory agents, cycloplegics, antimetabolites, biologics, and others. Among these range of therapeutics, corticosteroids is estimated to project a considerable CAGR during the forecast period. The corticosteroids are predominantly used as a first treatment option for anterior uveitis, owing to which, the demand is high for corticosteroids across the globe.
Geographically, the global anterior uveitis treatment market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to contribute a significant share in the global market. The well-developed healthcare infrastructure and presence of key market players, such as AbbVie Inc. and Alimera Sciences, Inc., is driving the market growth in the region. Moreover, the range of products under clinical trial of the market players based in North America is expected to further augment the market growth during the forecast period. In addition, Asia-Pacific is expected to project a considerable growth during the forecast period. This growth is backed by the rising prevalence of eye-related disorder, increasing disposable income, and medical tourism, especially in India, China, Malaysia, and Singapore.
The global anterior uveitis treatment market is influenced by product development and advancements conducted by the market players. The key players of the anterior uveitis treatment market include AbbVie Inc., Alimera Sciences, Inc., Santen Pharmaceutical Co., Ltd., Mylan NV, Allergan PLC, Cadila Pharmaceuticals Ltd., and EyePoint Pharmaceuticals, Inc. These players are playing a significant role in the growth of the anterior uveitis treatment market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.
The Report Covers
Comprehensive research methodology of the global anterior uveitis treatment market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global anterior uveitis treatment market.
Insights about market determinants which are stimulating the global market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
5. Market Segmentation
5.1. Global Anterior Uveitis Treatment Market by Therapeutics
5.1.2. Anti-inflammatory agents
5.1.6. Others (Anti-viral)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Aldeyra Therapeutics, Inc.
7.3. Alimera Sciences, Inc.
7.4. Allergan PLC
7.5. Bausch Health Companies Inc.
7.6. Cadila Pharmaceuticals Ltd.
7.7. Clearside Biomedical, Inc.
7.8. EyePoint Pharmaceuticals, Inc.
7.9. Mylan NV
7.10. Novartis AG
7.11. Pfizer Inc.
7.12. Prometheus Laboratories Inc.
7.13. Santen Pharmaceutical Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/8j6f4n
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900